O
OrbiMed Portfolio holdings
AUM
$3.98B
This Quarter Return
+7.57%
1 Year Return
+13.05%
3 Year Return
+159.74%
5 Year Return
+207.27%
10 Year Return
+1,027.33%
AUM
$4.43B
AUM Growth
–
Cap. Flow
+$4.4B
Cap. Flow
% of AUM
99.27%
Top 10 Holdings %
Top 10 Hldgs %
40.13%
Holding
117
New
107
Increased
–
Reduced
–
Closed
–
Top Buys
| 1 |
Amgen
AMGN
|
$258M |
| 2 |
Gilead Sciences
GILD
|
$247M |
| 3 |
Biogen
BIIB
|
$221M |
| 4 |
Merck
MRK
|
$192M |
| 5 |
Viatris
VTRS
|
$155M |
Top Sells
No sells this quarter
Sector Composition
| 1 | Healthcare | 85.21% |
| 2 | Financials | 2.18% |
| 3 | Technology | 0.15% |
| 4 | Utilities | 0.01% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Amgen
AMGN
$155B
| $258M | 5.48% | +2,619,400 | New | +$258M |
|
|
2
Gilead Sciences
GILD
$140B
| $247M | 5.24% | +4,821,800 | New | +$247M |
|
|
3
Biogen
BIIB
$19.4B
| $221M | 4.68% | +1,025,800 | New | +$221M |
|
|
4
Merck
MRK
$210B
| $192M | 4.06% | +4,125,400 | New | +$192M |
|
|
5
Viatris
VTRS
$12.3B
| $155M | 3.28% | +4,987,000 | New | +$155M |
|
6
Thermo Fisher Scientific
TMO
$186B
| $151M | 3.2% | +1,786,000 | New | +$151M |
|
7
Bristol-Myers Squibb
BMY
$96B
| $148M | 3.15% | +3,322,000 | New | +$148M |
|
|
CELG
8
DELISTED
Celgene Corp
CELG
| $145M | 3.07% | +1,236,400 | New | +$145M |
|
9
Pfizer
PFE
$141B
| $137M | 2.91% | +4,903,300 | New | +$137M |
|
10
Illumina
ILMN
$15.8B
| $124M | 2.62% | +1,651,800 | New | +$124M |
|
11
Incyte
INCY
$16.5B
| $123M | 2.61% | +5,606,000 | New | +$123M |
|
12
HCA Healthcare
HCA
$94.5B
| $121M | 2.57% | +3,366,300 | New | +$121M |
|
|
ESRX
13
DELISTED
Express Scripts Holding Company
ESRX
| $118M | 2.5% | +1,907,170 | New | +$118M |
|
|
ONXX
14
DELISTED
ONYX PHARMACEUTICALS INC
ONXX
| $102M | 2.16% | +1,175,000 | New | +$102M |
|
15
Elevance Health
ELV
$71.8B
| $97.1M | 2.06% | +1,187,000 | New | +$97.1M |
|
|
AET
16
DELISTED
Aetna Inc
AET
| $96.5M | 2.05% | +1,519,000 | New | +$96.5M |
|
|
ICPT
17
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $96.4M | 2.04% | +2,150,634 | New | +$96.4M |
|
18
Insulet
PODD
$23.9B
| $95.8M | 2.03% | +3,048,500 | New | +$95.8M |
|
|
AGN
19
DELISTED
Allergan plc
AGN
| $82.4M | 1.75% | +653,200 | New | +$82.4M |
|
20
Agilent Technologies
A
$35.7B
| $79.3M | 1.68% | +1,854,000 | New | +$79.3M |
|
21
UnitedHealth
UNH
$281B
| $79.1M | 1.68% | +1,208,000 | New | +$79.1M |
|
22
Regeneron Pharmaceuticals
REGN
$61.5B
| $79M | 1.67% | +351,100 | New | +$79M |
|
23
BioMarin Pharmaceuticals
BMRN
$11.2B
| $74.8M | 1.58% | +1,341,200 | New | +$74.8M |
|
24
AbbVie
ABBV
$372B
| $73.5M | 1.56% | +1,777,000 | New | +$73.5M |
|
|
INFI
25
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
| $73.2M | 1.55% | +4,520,800 | New | +$73.2M |
|